GlassScriptPhysician profile
James J Presley
NPI 1386604395
$2,162.30
in general payments reported to CMS, 2019-2025
29 companies · $289 in 2025
The $289 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $653 · 2020: $351 · 2021: $403 · 2022: $13.04 · 2024: $454 · 2025: $289.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $743.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $742.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $294.21 | 2019-2025 | Aptima, Thinprep 2000 Processor |
| Abbvie INC. | $286.78 | 2019-2025 | |
| Amgen INC. | $228.05 | 2019-2020 | |
| Astellas Pharma US INC | $184.32 | 2022-2025 | Veozah |
| Therapeuticsmd, INC. | $135.92 | 2019-2021 | |
| Duchesnay USA Incorporated | $114.40 | 2019 | |
| Phathom Pharmaceuticals, INC. | $111.09 | 2024 | Voquezna |
| Daiichi Sankyo INC. | $94.04 | 2020-2021 | |
| Medtronic, INC. | $92.33 | 2024 | Interstim |
| Merck Sharp & Dohme LLC | $78.39 | 2025 | Pifeltro, Capvaxive |
| Coopersurgical, INC. | $71.51 | 2019-2021 | |
| Boston Scientific Corporation | $50.27 | 2024-2025 | General - Pain Management |
| Applied Medical Resources Corporation | $37.77 | 2019 | |
| Amag Pharmaceuticals, INC. | $37.36 | 2019 | |
| Millicent US INC | $35.48 | 2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $35.45 | 2021 | |
| Pfizer INC. | $31.22 | 2019-2021 | |
| Agile Therapeutics, INC. | $29.53 | 2021 | |
| Exeltis, USA INC. | $26.59 | 2020-2021 | |
| Minerva Surgical, INC | $25.42 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $24.89 | 2025 | |
| Kci USA, INC. | $24.50 | 2021 | |
| Abbott Laboratories | $24.07 | 2024 | Freestyle Libre 3 |
| Corcept Therapeutics | $22.20 | 2025 | Korlym |
| Fresenius Kabi USA, LLC | $19.39 | 2024 | Idacio |
| Gilead Sciences, INC. | $19.08 | 2025 | |
| Organon LLC | $14.55 | 2025 | Nexplanon |
| Qiagen, LLC | $13.49 | 2025 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Presley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.